Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar User Fee Negotiations Won't Start Until 2016

Executive Summary

Mid-December kick-off meeting puts emerging user fee program on much later track than others.


Related Content

Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload
PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows
Biosimilar User Fee Agreement Reached, But Will Require Appropriations Boost
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
PDUFA V Agreement Appears Set Between FDA And Industry